Recent studies have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and DA neurotransmission. While GIP activators are widely employed for addressing type 2 T2DM, their unexpected consequences on reward circuits, specifically influenced by dopa